News

Important information

BIOJAMP : A Range of Biosimilars for a Seamless Approach

November 15, 2022
The JAMP Pharma Group launches Pr JAMP Apremilast, a new generic alternative for the treatment of plaque psoriasis and psoriatic arthritis
October 20, 2022
Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care
June 7, 2022
Jason Frame Recognized by the Neighbourhood Pharmacy Association of Canada as Recipient of Distinguished Associate of the Year Award
May 19, 2022
JAMP Pharma Group Launches PrJAMP Teriflunomide, a New Generic for the Treatment of Patients with Relapsing-Remitting Multiple Sclerosis
April 27, 2022
Biosimilar drugs: BIOJAMP(MC) and Accessa join forces to simplify access to Simlandi(MC)
April 14, 2022
JAMP Pharma Launches SIMLANDI™, a NEW High-Concentration, Low Volume, Citrate-Free formulation, Biosimilar to Humira®, in Canada
February 28, 2022
JAMP Pharma Group launches a new generic drug for the treatment of attention deficit hyperactivity disorder (ADHD)
February 1, 2022
BIOJAMP: A Range of Biosimilars for a Seamless Approach
January 10, 2022
JAMP and Alvotech Announce Canadian Approval of SIMLANDI™, a High-Concentration Biosimilar to Humira®, Providing Access to Previously Unavailable Versions in Canada
November 17, 2020
Appointment of Bruno Mäder as President and COO